初诊多发性骨髓瘤患者经硼替佐米联合化疗后1年内复发的相关因素回归分析  

Recurrence Related Factors of Newly Diagnosed Multiple Myeloma within 1 Year Relapse after Bortezomib Combined with Chemotherapy

作　　者：林树洪[1] 蔡宋浩[1] 于瑞芳[1] LIN Shu-hong;CAI Song-hao;YU Rui-fang(Department of Hematology,Shantou Central Hospital,Shantou Guangdong 515031,China)

机构地区：[1]汕头市中心医院血液科,广东汕头515031

出　　处：《湖北科技学院学报（医学版）》2020年第4期309-312,共4页Journal of Hubei University of Science and Technology(Medical Sciences)

摘　　要：目的探讨初诊多发性骨髓瘤(MM)患者经硼替佐米联合化疗后1年内复发的相关因素。方法将我院血液科接受以硼替佐米联合化疗方案的初诊82例MM患者作为研究对象,化疗后均接受至少1年随访,分为复发组(24例)及未复发组(58例),收集年龄、性别、DS分期、ISS分期、化疗周期、癌胚抗原(CEA)、甲胎蛋白(AFP)、降钙素原(PCT)、β2微球蛋白(β2-MG)、C反应蛋白(CRP)、父母肿瘤史、尿免疫球蛋白κ轻链及复杂核型共13个指标,行单因素分析及Logistic分析。结果复发组与未复发组在年龄、DS分期、ISS分期、CEA、PCT、β2-MG、父母肿瘤史及复杂核型等因素差异有统计学意义(P<0.05)。Logistic分析显示高龄(OR=3.991,95%CI:1.580~22.773)、复杂核型(OR=4.874,95%CI:1.903~26.150)、高DS分期(OR=1.504,95%CI:1.101~4.294)及高ISS分期(OR=1.525,95%CI:1.194~4.260)是初诊MM患者经硼替佐米联合化疗后1年内复发的危险性因子(P<0.05)。结论高龄、复杂核型、高DS分期及高ISS分期是初诊MM经硼替佐米联合化疗后1年内复发的危险因素。Objective To explore the recurrence related factors of newly diagnosed multiple myeloma(MM)within 1 year relapse after Bortezomib combined with chemotherapy.Methods 82 newly diagnosed MM patients that received Bortezomib combined with chemotherapy from the department of Hematology of Shantou Central Hospital were selected for this study.All patients were followed up for at least 1 year after chemotherapy and divided into relapse groups(24 cases)and non-relapsed group(58 cases).The information collected inclueded age,sex,DS staging,ISS staging,chemotherapy cycle,carcinoembryonic antigen(CEA),alpha-fetoprotein(APP),Procalcitonin(PCT),β2 microspheres Protein(β2-MG),C-reactive protein(CRP),parental tumor history,urinary immunoglobulin kappa light chain and complex karyotype.Univariate analysis and Logistic regression analysis were performed.Results There were significant differences between the relapsed group and the non-relapsed group in age,DS stage,ISS stage,CEA,PCT,β2-MG,Parental tumor history,and complex karyotype,P<0.05.Logistic regression analysis further showed advanced age[aOR=3.991,95%CI:1.580~22.773],complex karyotype[aOR=4.874,95%CI:1.903~26.150],high DS stage[aOR=1.504,95%CI:1.101~4.294]and high ISS stage[aOR=1.525,95%CI:1.194~4.260]were signifcant risk factors for recurrence within 1 year of newly diagnosed MM patients after Bortezomib combined with chemotherapy.Conclusion Old age,complex karyotype,high DS stage,and high ISS stage are risk factors of newly diagnosed MM within 1 year relapse after Bortezomib combined with chemotherapy.

关 键 词：初诊多发性骨髓瘤 硼替佐米 联合化疗 复发 危险因素 

分 类 号：R733.3[医药卫生—肿瘤]